- In May 2025, Clario (US) acquired WCG Clinical's (US) eCOA business, a strategic move to bolster its leadership in digital endpoint data solutions, particularly for neuroscience clinical trials. This acquisition expands Clario's comprehensive endpoint data platform, enabling better support for complex trial environments and further solidifying its position in the rapidly evolving eCOA landscape
- In May 2025, Critical Path Institute (US) continued its "eCOA: Getting Better Together" initiative, aiming to unify sponsors, technology vendors, and regulators. This collaborative effort, extending through March 2025, focuses on establishing pre-competitive best practices and a common lexicon for eCOA data capture, promoting standardization and accelerating adoption across diverse regions
- In November 2023, Clinical Ink enhanced its patient engagement suite by incorporating Observia's SPUR behavioral diagnostic tool. This integration merges behavioral assessment with lifestyle modification, eCOA, eSource, and Digital Biomarkers, aiming to provide a more holistic understanding of patient behavior and improve trial outcomes
- In October 2023, Clario entered a strategic partnership with Trial Data, a decentralized clinical trial (DCT) service provider. This collaboration strengthens Clario's presence in China's clinical trial arena, combining their expertise to deliver state-of-the-art decentralized trial solutions and advance patient-centric approaches in the region
- In December 2022, Suvoda LLC, an eCOA clinical trial technology company, introduced its electronic clinical outcome assessments (eCOA) design toolkit. This toolkit is created to integrate smoothly with Suvoda IRT and eConsent, addressing historical inadequacies in eCOA implementation and aiming to streamline the design process
